Table 2. . Summary of cost–effectiveness analysis results, base case.
| Outcome | Sotagliflozin group | SoC group | Difference | |
|---|---|---|---|---|
| QALYs (per patient, 30 years) | Stable HF | 2.249 | 1.808 | 0.441 |
| Rehospitalization | 0.041 | 0.051 | -0.010 | |
| ED visit | 0.016 | 0.022 | -0.006 | |
| Total | 2.305 | 1.880 | 0.425 | |
| Costs (2022 USD, per patient, 30 years) | Pharmacy | $21,877 | $0 | $21,877 |
| Rehospitalization | $7537 | $9597 | -$2060 | |
| ED visit | $1072 | $1490 | -$418 | |
| Adverse event treatment | $1466 | $1492 | -$26 | |
| Total | $31,953 | $12,579 | $19,374 | |
| ICER | $45,596 | |||
ED: Emergency department; HF: Heart failure; ICER: Incremental cost–effectiveness ratio; QALY: Quality-adjusted life year; SoC: Standard of care; USD: US dollar.